ストックスクリーナーアプリを入手
1.72
4.97%
-0.09
アフターアワーズ：
1.72
前日終値:
$1.81
開ける：
$1.84
24時間の取引高:
764.13K
Relative Volume:
0.85
時価総額：
$237.51M
収益：
$15.53M
当期純損益:
$-52.71M
株価収益率:
-3.4229
EPS:
-0.5025
ネットキャッシュフロー:
$-59.00M
1週間 パフォーマンス:
-6.01%
1か月 パフォーマンス:
+14.67%
6か月 パフォーマンス:
-17.31%
1年 パフォーマンス:
-21.10%
1日の値動き範囲:
$1.72
$1.87
1週間の範囲:
$1.69
$1.945
52週間の値動き範囲:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.72 | 256.84M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | Oppenheimer | Outperform |
| 2025-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-10 | アップグレード | Citigroup | Neutral → Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-29 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-02-11 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | ダウングレード | Stifel | Buy → Hold |
| 2022-02-01 | 開始されました | Raymond James | Strong Buy |
| 2021-05-03 | 開始されました | Stifel | Buy |
| 2021-03-25 | 繰り返されました | Citigroup | Buy |
| 2020-11-03 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-12-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-11-15 | 開始されました | Citigroup | Buy |
| 2018-09-19 | 開始されました | Evercore ISI | Outperform |
| 2017-09-26 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-06-20 | 開始されました | Chardan Capital Markets | Neutral |
| 2014-10-15 | 開始されました | Deutsche Bank | Buy |
| 2014-10-13 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Proqr Therapeutics N V (PRQR) 最新ニュース
PRQRProQR Therapeutics N.V Options - Finviz
Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa
Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan
0PQ Forecast — Price Target — Prediction for 2027 - TradingView
PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus
Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus
PRQR Maintained by Chardan Capital -- Price Target Lowered to $3 - GuruFocus
ProQR Therapeutics N.V. Actuals & Estimates (DUS:0PQ) - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR) - TradingView
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - TipRanks
ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan
Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Price to sales forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProQR Therapeutics NVPhase 2 Program Expec - Moomoo
ProQR Therapeutics N.V. Actuals & Estimates (MUN:0PQ) - TradingView
PRQR Forecast — Price Target — Prediction for 2027 - TradingView
ProQR posts early-stage trial data for liver disease candidate - MSN
ProQR Therapeutics (PRQR) Reports Progress in Phase 1 Study of A - GuruFocus
Price to earnings forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Price to earnings forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (LS:A12B97) - TradingView
ProQR Therapeutics (PRQR) Launches $50M Share Offering with Eli Lilly Participation - GuruFocus
ProQR Therapeutics reports positive Phase 1 data for AX-0810 RNA editing candidate - grafa.com
A12B97 Forecast — Price Target — Prediction for 2027 - TradingView
ProQR prices $50M stock offering at $1.81 per share - Investing.com UK
ProQR's $59M Raise: A Strategic Bet on RNA Editing's Future - BriefGlance
ProQR prices $50M stock offering at $1.81 per share By Investing.com - Investing.com Australia
Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap - Barchart.com
ProQR reports positive Phase 1 data for AX-0810 in healthy volunteers - Investing.com Nigeria
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement - markets.businessinsider.com
ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint - marketscreener.com
ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering - marketscreener.com
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform - TipRanks
ProQR Therapeutics NV announced that its investigational therapy AX-422 for mucopolysaccharidosis type I (MPS1) is expected to submit a Clinical Trial Application (CTA) in early 2027. - Bitget
ProQR (PRQR) Phase 1 AX-0810 data clinically validate Axiomer RNA editing - Stock Titan
ProQR Therapeutics Reports Positive Phase 1 Target Engagement Data for AX-0810, Supporting Advancement of NTCP Franchise - Quiver Quantitative
ProQR's RNA Editing Breakthrough: A New Dawn for Liver Disease Treatment? - BriefGlance
Enterprise value to revenue forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
ProQR Therapeutics N.V. announced that it expects to receive $9.199996 million in funding from Eli Lilly and Company - marketscreener.com
ProQR Therapeutics NV (PRQR) Institutional Confidence - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Proqr Therapeutics N V (PRQR) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):